To test this hypothesis, we sought to elucidate the impact of SMARCB1 loss and subsequent STAT3 pathway activation on bladder orthotopic tumor growth, metastasis, and BLCA disease-specific survival. This evidence concerns the gene STAT3 and bladder transitional cell carcinoma.